Close
FINDING CURES TOGETHER<sup>SM</sup>

Advancing Precision Medicine Drug Development: Incorporation of Real-World Data and Other Novel Strategies

Program 

Thursday, Jan. 9

Friday, Jan. 10


Saturday, Jan. 11


Thursday, Jan. 9

Welcome and Opening Keynote Lectures
6:30-8:30 p.m.

Title to be announced
Amy P. Abernathy, U.S. Food and Drug Administration, Silver Spring, Maryland

Title to be announced
Deborah Schrag, Dana-Farber Cancer Institute, Boston, Massachusetts

Panel Discussion


Opening Reception
8:30-10 p.m.


Top of page


Friday, Jan. 10

Continental Breakfast
7-8 a.m.


Plenary Session 1: Machine Learning in Precision Oncology
8-9:45 a.m.

Title to be announced
David Haussler, University of California, Santa Cruz, California

Drug predictive computational evaluations
Benjamin Haibe-Kains, Princess Margaret Cancer Centre, Toronto, ON, Canada

Title to be announced
Evis Sala, University of Cambridge, Cambridge, United Kingdom

Panel Discussion

Break
9:45-10 a.m.


Plenary Session 2: Databases and EHRs
10-11:45 a.m.

Title to be announced
Neal J. Meropol, Flatiron Health, New York, New York

Title to be announced
Corrie Painter, Broad Institute of Harvard and MIT / CountMeIn, Cambridge, Massachusetts

Title to be announced
Liz Salmi, OpenNotes / Beth Israel Deaconess Medical Center, Boston, Massachusetts

Panel Discussion


Poster Session A / Lunch
12-2:45 p.m.


Plenary Session 3: Real-Time Patient Monitoring
Session Moderator: Elaine R. Mardis, Nationwide Children's Hospital, Columbus, Ohio
3-4:45 p.m.

Speakers to be announced


Dinner on Own
4:45 p.m.

Top of page


Saturday, Jan. 11

Continental Breakfast
7-8 a.m.


Plenary Session 4: Novel Drug Development Approaches / Drugging Difficult Targets
8-9:45 a.m.

Title to be announced
José Baselga, AstraZeneca, Gaithersburg, Maryland

Title to be announced
Jeffrey A. Engelman, Novartis, Cambridge, Massachusetts

Title to be announced
Levi A. Garraway, Eli Lilly and Company, Indianapolis, Indiana

Panel Discussion


Break
9:45-10 a.m.


Plenary Session 5: What Constitutes Adequate Screening?
10-11:45 a.m.

Title to be announced
Elaine R. Mardis, Nationwide Children's Hospital, Columbus, Ohio

Title to be announced
Alexandra Snyder, Merck & Co., Rahway, New Jersey

Additional speaker to be announced

Panel Discussion


Free Time / Lunch on Own
12-2 p.m.


Plenary Session 6: Unique Clinical Trial Designs
2:15-4 p.m.

Title to be announced
Jean-Charles Soria, AstraZeneca, Gaithersburg, Maryland

Title to be announced
Emile E. Voest, Netherlands Cancer Institute, Amsterdam, Netherlands

Title to be announced
David M. Hyman, Memorial Sloan Kettering Cancer Center, New York, New York

Panel Discussion


Poster Session B / Reception
4:15-6:45 p.m.


Dinner on Own
6:45 p.m.

Top of page


Sunday, Jan. 12

Continental Breakfast
7-8 a.m.


Keynote Lectures
8-9:20 a.m.

Title to be announced
Howard C. Bauchner, Journal of the American Medical Association, Chicago, Illinois

Title to be announced
Richard D. Klausner, GRAIL, Inc., Menlo Park, California


Plenary Session 7: Panel Discussion on Perspectives from Biotech and the Finance Sector
Moderator: Richard D. Klausner, GRAIL, Inc., Menlo Park, California. Additional moderator to be announced.
9:30-10:45 a.m.

James Tanenbaum, Foresite Capital, San Francisco, California
Thomas G. Roberts, Farallon Capital, San Francisco, California
Philip Dreyfuss, Farallon Capital, San Francisco, California


Break
10:45-11 a.m.


Plenary Session 8: MRD / Advanced Diagnostics
11 a.m.-12:45 p.m.

Title to be announced
Eliezer M. Van Allen, Dana-Farber Cancer Institute, Boston, Massachusetts

Title to be announced
Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada

Additional speaker to be announced

Panel Discussion


Closing Remarks and Departure
12:45 p.m.


Top of page